RECRUITING

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Talk to us

Conditions

Lung CancerLung Cancer MetastaticBrain MetastasesNon Small Cell Lung CancerPositron Emission Tomography

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Official Title

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer

Quick Facts

Study Start:2022-09-13
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05452005

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Men and women age \>18 yrs
  2. 2. Biopsy proven NSCLC with brain metastases (treated or untreated)
  3. 3. Life-expectancy of ≥3 months in the opinion of the treating physician
  4. 4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
  5. 5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
  6. 6. Ability to understand and willingness to sign a written informed consent document.
  7. 7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
  8. 8. \[18F\]-FDG PET/CT within 21 days of enrollment
  9. 9. MRI brain within 21 days of enrollment
  10. 10. Eastern Cooperative Oncology Group Performance Status ≤ 2
  11. 11. Glomerular filtration rate (GFR) ≥ 60
  1. 1. Pregnant or lactating women
  2. 2. Prisoners
  3. 3. Concurrent malignancy of a different histology that could confound imaging interpretation
  4. 4. Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)

Contacts and Locations

Study Contact

Principal Investigator
CONTACT
916-734-5536
jlsutcliffe@ucdavis.edu
Julie L Sutcliffe
CONTACT
9167345536
jlsutcliffe@ucdavis.edu

Principal Investigator

Julie L. Sutcliffe, PhD
PRINCIPAL_INVESTIGATOR
The Regents of the University of California (Davis)

Study Locations (Sites)

The University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
United States

Collaborators and Investigators

Sponsor: University of California, Davis

  • Julie L. Sutcliffe, PhD, PRINCIPAL_INVESTIGATOR, The Regents of the University of California (Davis)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-13
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2022-09-13
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Positron Emission Tomography

Additional Relevant MeSH Terms

  • Lung Cancer
  • Lung Cancer Metastatic
  • Brain Metastases
  • Non Small Cell Lung Cancer